Whittier Trust Co. Has $178,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Whittier Trust Co. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 340 shares of the biopharmaceutical company’s stock after selling 500 shares during the quarter. Whittier Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $178,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Klingman & Associates LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $201,000. Phoenix Financial Ltd. increased its holdings in Regeneron Pharmaceuticals by 12.3% in the 2nd quarter. Phoenix Financial Ltd. now owns 583 shares of the biopharmaceutical company’s stock valued at $306,000 after buying an additional 64 shares during the period. Cidel Asset Management Inc. increased its holdings in Regeneron Pharmaceuticals by 20.4% in the 2nd quarter. Cidel Asset Management Inc. now owns 461 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 78 shares during the period. International Assets Investment Management LLC increased its holdings in Regeneron Pharmaceuticals by 30.0% in the 2nd quarter. International Assets Investment Management LLC now owns 724 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 167 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $27,853,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 0.4%

REGN opened at $577.95 on Friday. The firm’s 50-day simple moving average is $576.32 and its 200-day simple moving average is $562.58. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $943.83. The firm has a market cap of $61.26 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.79 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 EPS. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on REGN. Jefferies Financial Group boosted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Sanford C. Bernstein boosted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Citigroup upped their target price on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $802.35.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.